comparemela.com

Latest Breaking News On - Nasdaq cyad - Page 1 : comparemela.com

Celyad Oncology (NASDAQ:CYAD) Shares Pass Above Fifty Day Moving Average of $0.69

Celyad Oncology SA (NASDAQ:CYAD – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.69 and traded as high as $0.81. Celyad Oncology shares last traded at $0.75, with a volume of 8,985 shares. Celyad Oncology Stock Down 5.1 […]

Celyad-oncology-company-profile
Celyad-oncology
Get-free-report
Oncology-stock-down
Celyad-oncology-daily
Nasdaq-cyad
Cyad
Medical
Stocks
Technicals

Celyad Oncology Reports First Half 2023 Financial Results

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement.

Belgium
United-states
London
City-of
United-kingdom
Walloon-region
Waals-gewest
Mont-saint-guibert
Boston
Massachusetts
Parc
Region-flamande

Celyad Oncology to announce full year 2022 financial

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company.

Mont-saint-guibert
Waals-gewest
Belgium
New-york
United-states
David-georges
Caroline-lonez
Exchange-commission
Business-development
Wrd-communications
Belgium-fixed
Belgium-mobile

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.